Insilico Medicine has nominated ISM9077, an AI-designed compound targeting a previously undrugged protein, as a preclinical candidate for dry age-related macular degeneration, uveitis, and dry eye disease. Preclinical data show the molecule outperforms current therapies across these indications while maintaining favorable pharmacokinetic properties for both oral and topical administration.
Key Points
- AI-designed molecule outperforms existing therapies in three major eye diseases
- Demonstrates 2–5.5× retinal-to-plasma exposure ratio supporting drug delivery
- Represents 32nd preclinical candidate from Insilico since 2021
Longevity Analysis
Age-related macular degeneration and dry eye disease represent significant drivers of visual decline and quality-of-life impairment in aging populations. The translation of generative chemistry platforms into candidate molecules with measurable pharmacokinetic advantages accelerates the traditional drug discovery timeline, potentially bringing new mechanisms of action to patients faster than conventional approaches. This candidate's favorable retinal exposure and bioavailability profile suggests the underlying computational design addressed key barriers that have historically limited therapeutic options in ocular disease.
Original published by LT Wire.